RenovoRx Inc (RNXT NASDAQ) stock market data APIs
$2.4041
-0.05(-2.1%)
as of September 4, 2026
Try our APIs with
free plan!
RenovoRx Inc Financial Data Overview
Price chart is built with
Anychart
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Prev. Close
2.4041
Open
2.3522
High
2.5328
Low
2.2889
52 wk Range
0.701-2.59
Market Cap
108 M
Shares Outstanding
45 130 K
Revenue
1 976 K
EPS
-0.05
Beta
1.121
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with RenovoRx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RenovoRx Inc data using free add-ons & libraries
Get RenovoRx Inc Fundamental Data
RenovoRx Inc Fundamental data includes:
- Net Revenue: 1 976 K
- EBITDA: -13 034 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RenovoRx Inc News
New
These low-priced stocks are flashing overbought signals
[Wall Street New York stock exchange stock market] alexsl Several sub-$10 stocks are flashing elevated momentum signals, with a handful already entering traditionally overbought territory as recent r...
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
RenovoRx, Inc. MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology t...
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
RenovoRx, Inc. MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology th...
RenovoRx Q2 Earnings Call Highlights
Key Points Interested in RenovoRx, Inc.? Here are five stocks we like better. Record commercial growth: Second-quarter revenue rose 115% year over year to $909,000, supported by increased RenovoCath ...
Get RenovoRx Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
